105 related articles for article (PubMed ID: 21142760)
1. Anticipating the impact of Bruesewitz v. Wyeth on Vaccine And Medical Countermeasure Injury Compensation And Availability.
Courtney B; Morhard R
Biosecur Bioterror; 2010 Dec; 8(4):315-20. PubMed ID: 21142760
[No Abstract] [Full Text] [Related]
2. Update on vaccine liability in the United States: presentation at the National Vaccine Program Office Workshop on strengthening the supply of routinely recommended vaccines in the United States, 12 February 2002.
Evans G
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S130-7. PubMed ID: 16447135
[TBL] [Abstract][Full Text] [Related]
3. Safety, supply, and suits--litigation and the vaccine industry.
Kesselheim A
N Engl J Med; 2011 Apr; 364(16):1485-7. PubMed ID: 21506740
[No Abstract] [Full Text] [Related]
4. Vaccine liability in the Supreme Court: forging a social compact.
Kraemer JD; Gostin LO
JAMA; 2011 May; 305(18):1900-1. PubMed ID: 21558521
[No Abstract] [Full Text] [Related]
5. Bruesewitz v Wyeth: ensuring the availability of children's vaccines.
McAbee GN; McDonnell WM; Donn SM
Pediatrics; 2011 Jun; 127(6):1180-1. PubMed ID: 21576312
[No Abstract] [Full Text] [Related]
6. A child's view of recovery under the National Childhood Vaccine Act or "He who hesitates is lost".
Pertnoy LD
Spec Law Dig Health Care Law; 1999 Aug; (245):9-33. PubMed ID: 10558077
[No Abstract] [Full Text] [Related]
7. Market share liability for pharmaceuticals. The distinction between DES and DPT.
Fern FH; McHugh LS
J Leg Med; 1990 Dec; 11(4):391-426. PubMed ID: 2292665
[No Abstract] [Full Text] [Related]
8. The National Childhood Vaccine Injury Act and the supreme court's interpretation.
Blake V
Virtual Mentor; 2012 Jan; 14(1):31-4. PubMed ID: 23116914
[No Abstract] [Full Text] [Related]
9. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
10. Vaccine shortages persist despite lessons from past.
Traynor K
Am J Health Syst Pharm; 2004 Dec; 61(23):2458, 2460, 2462. PubMed ID: 15595217
[No Abstract] [Full Text] [Related]
11. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
12. Guillain-Barré syndrome due to swine influenza and neurologic damage due to DTP vaccines: the touch of statistics.
Sepkowitz S
South Med J; 1993 Jun; 86(6):699-702. PubMed ID: 8506498
[No Abstract] [Full Text] [Related]
13. Adult immunization.
Treat Guidel Med Lett; 2014 Jun; 12(142):39-48. PubMed ID: 24869519
[No Abstract] [Full Text] [Related]
14. A Global Vaccine Injury Compensation System.
Halabi SF; Omer SB
JAMA; 2017 Feb; 317(5):471-472. PubMed ID: 28114657
[No Abstract] [Full Text] [Related]
15. National Vaccine Injury Compensation Program (VICP): effective date provisions of coverage of certain vaccines to the vaccine injury table--HRSA. Final rule.
Fed Regist; 1998 May; 63(90):25777-8. PubMed ID: 10179332
[TBL] [Abstract][Full Text] [Related]
16. Wyeth Pharmaceutical's perspective on vaccine production.
Stiles GL
Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
[No Abstract] [Full Text] [Related]
17. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
[TBL] [Abstract][Full Text] [Related]
18. [On the elimination of multidose vaccines containing thimerosal].
Calvo M
Rev Chilena Infectol; 2013 Aug; 30(4):346-9. PubMed ID: 24248102
[No Abstract] [Full Text] [Related]
19. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
Levy E
Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
[No Abstract] [Full Text] [Related]
20. Risk management ... National Childhood Vaccine Injury Act of 1986.
Toreki W
Trends Health Care Law Ethics; 1992; 7(2):41-4. PubMed ID: 1576475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
